Published 1 month ago • loading... • Updated 1 month ago

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead - Amgen (NASDAQ:AMGN)

Summary by Benzinga

On Tuesday, Amgen Inc (NASDAQ:AMGN) reported fourth-quarter sales of $9.10 billion, up 11% year-over-year, beating the consensus of $8.9 billion. Product sales grew 11%, primarily driven by 14% volume growth. Excluding sales from the Horizon Therapeutics acquisition, product sales grew 10%, driven by 15% volume growth. Ten products delivered at least double-digit sales growth in the fourth quarter, including Repatha (evolocumab), Blincyto (blin…

5 Articles

All

Left

Center

Right

Benzinga

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead - Amgen (NASDAQ:AMGN)

1 month ago·New York, United States

Read Full Article

The Motley Fool

Amgen Surpasses Q4 Earnings Forecasts @themotleyfool #stocks $AMGN

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS of $5.08 and revenue of $8.88 billion, but Amgen reported $5.31 in EPS and $9.1 billion in revenue, showcasing double-digit year-on-year growth in both metrics. Overall, the quarter demonstrated Amgen's effective execution amid a competitive landscape.Me…

1 month ago·Alexandria, United States

Read Full Article

Investing News Network

Amgen, Merck and Pfizer Release Latest Quarterly Earnings, Share 2025 Plans

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4), Amgen (NASDAQ:AMGN), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) released financial results for the most recent quarter, providing critical data points for evaluating investment potential.Amgen reports strong Q4, will focus on trials in 2025Amgen’s financial results for Q4 and the full 2024 year reveal quarterly revenue of o…

1 month ago

Read Full Article

themarketsdaily.com

Commonwealth Financial Services LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Commonwealth Financial Services LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,859 shares of the medical research company’s stock after buying an additional […]

1 month ago

Read Full Article

modernreaders.com

abrdn plc Cuts Holdings in Amgen Inc. (NASDAQ:AMGN)

abrdn plc lowered its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 13.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 889,240 shares of the medical research company’s stock after selling 136,407 shares during the period. abrdn plc owned approximately 0.17% of Amgen worth $230,851,000 as of its most recent SEC filing. Other hedge funds and other in…

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year